Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared a post on LinkedIn:
“The primary clinical and biomarker results of SURE02 are released today in The Lancet Oncology simultaneously with the poster presentation.
Is was a huge effort. Key observations:
- first trial of ADC+IO approach in a perioperative setting of MIBC within a bladder-sparing strategy
- clinical cCR use is consistent with Milan consensus definition BUT was not the biomarker used for bladder preservation
- reTURBT vs RC was an informed patient decision
- cCR rate 39%
- 12-month EFS in ITT 71% raising to 90% in CR pts
- no metastases events in the reTURBT group, indicating that delaying RC can be safe within a maintenance therapy design
- cCR enriched in Luminal subtype tumors pointing to the contribution of SG over pembro
- Sacituzumab dose was 7.5 mg/kg with GCSF support resulting in no G4 events and very manageable tolerability
TROP2 targeting can be effective in newer flexible strategies for pts with MIBC.”
Title: Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
Authors: Andrea Necchi, Brigida Maiorano, Joep de Jong, James Proudfoot, Giuseppe Basile, Antonio Cigliola, Chiara Mercinelli, Valentina Tateo, Michela Piacentini, Giovanni Pastorino, Gaia Latini, Enrico Tomasi, Elai Davicioni, Marco Moschini, Giorgio Brembilla, Maurizio Colecchia, Francesco de Cobelli, Alberto Briganti, Jeffrey Ross, Dean Pavlick, Francesco Montorsi
Read the Full Article.
Other articles featuring Andrea Necchi on OncoDaily.